ЭФФЕКТИВНОСТЬ ИНГИБИТОРОВ КАЛЬЦИНЕВРИНА В ЛЕЧЕНИИ СТЕРОИДРЕЗИСТЕНТНОГО НЕФРОТИЧЕСКОГО СИНДРОМА У ДЕТЕЙ
Ключевые слова:
стероидрезистентный нефротический синдром, ингибиторы кальциневрина, такролимусАннотация
Стероидрезистентный нефротический синдром (СРНС) у детей требует эскалации терапии за рамки глюкокортикоидов. Ингибиторы кальциневрина (ИКН) - циклоспорин А (ЦсА) и такролимус (ТАК) - являются основой терапии второй линии, однако сравнительные данные об их эффективности из Центральной Азии не опубликованы
##plugins.themes.default.displayStats.downloads##
Библиографические ссылки
1. Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children. Lancet. 2018;392(10141):61–74. С. 61–66
2. Trautmann A, Vivarelli M, Samuel S, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2020;35(8):1529–1561. С. 1529–1561
3. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003;362(9384):629–639. С. 629–636
4. Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008;14(9):931–938. С. 931–935
5. Buscher AK, Beck BB, Melk A, et al. Rapid response to cyclosporin A and favorable renal outcome in nongenetic versus genetic steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol. 2016;11(2):245–253. С. 245–250
6. Tejani A, Butt K, Rajpoot D, et al. Cyclosporine A induced remission of relapsing nephrotic syndrome in children. Kidney Int. 1987;32(5):760–764. С. 760–763
7. Ehrich JH, Brodehl J. Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Eur J Pediatr. 1993;152(4):357–361. С. 357–360
8. Choudhry S, Bagga A, Hari P, et al. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome. Am J Kidney Dis. 2009;53(5):760–769. С. 760–768
9. Li T, Wu HM, Wang F, et al. Tacrolimus versus cyclosporine for induction therapy of lupus nephritis. Cochrane Database Syst Rev. 2012;2012(3):CD008561. С. 1–30
10. Gulati A, Sinha A, Gupta A, et al. Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome. Kidney Int. 2012;82(10):1130–1135. С. 1130–1134
11. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1–S276. С. S155–S168 (Глава 6: СРНС)
12. Bierzynska A, McCarthy HJ, Soderquest K, et al. Genomic and clinical profiling of a national nephrotic syndrome cohort advocates a precision medicine approach to disease management. Kidney Int. 2017;91(4):937–947. С. 937–942
13. Sinha A, Bagga A, Banerjee S, et al. Steroid-sensitive nephrotic syndrome: revised guidelines. Indian Pediatr. 2021;58(5):461–481. С. 461–475
14. Ranganathan S, Krishnamurthy S, Rajesh NG, et al. Randomized trial of tacrolimus versus cyclosporine in steroid-resistant nephrotic syndrome: the TOPHI trial. Pediatr Nephrol. 2021;36(4):907–916. С. 907–913
15. Basu B, Mahapatra TK, Mondal N. Mycophenolate mofetil following rituximab in children with steroid-resistant nephrotic syndrome. Pediatrics. 2015;136(1):e132–e139. С. e132–e136
16. Gellermann J, Weber L, Pape L, et al. Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol. 2013;24(10):1689–1697. С. 1689–1695
17. Trautmann A, Schijvens AM, Lipska-Ziętkiewicz BS, et al. Long-term outcome in children with steroid-resistant nephrotic syndrome: a multicentre cohort study. Pediatr Nephrol. 2023;38(5):1473–1484. С. 1473–1480
